Cargando…
Quantifying the CDK inhibitor VMY-1-103’s activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI
The development of new small molecule-based therapeutic drugs requires accurate quantification of drug bioavailability, biological activity and treatment efficacy. Rapidly measuring these endpoints is often hampered by the lack of efficient assay platforms with high sensitivity and specificity. Usin...
Autores principales: | Sirajuddin, Paul, Das, Sudeep, Ringer, Lymor, Rodriguez, Olga C., Sivakumar, Angiela, Lee, Yi-Chien, Üren, Aykut, Fricke, Stanley T., Rood, Brian, Ozcan, Alpay, Wang, Sean S., Karam, Sana, Yenugonda, Venkata, Salinas, Patricia, Petricoin III, Emanuel, Pishvaian, Michael, Lisanti, Michael P., Wang, Yue, Schlegel, Richard, Moasser, Bahram, Albanese, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495823/ https://www.ncbi.nlm.nih.gov/pubmed/22983062 http://dx.doi.org/10.4161/cc.21988 |
Ejemplares similares
-
The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells
por: Ringer, Lymor, et al.
Publicado: (2014) -
The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells
por: Waye, Sarah, et al.
Publicado: (2015) -
Preclinical Studies of the Potent and Selective Nicotinic
α4β2 Receptor Ligand VMY-2-95
por: Kong, Hyesik, et al.
Publicado: (2014) -
Some interesting aspects of the VMI model
por: Scharff-Goldhaber, G
Publicado: (1970) -
VMI prueba Beery-Buktenica del desarrollo de la integración visomotriz y pruebas suplementarias de percepción visual y coordinación motriz
por: Beery, Keith E.
Publicado: (2000)